Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Havlin

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Seminars in Oncology|December 1, 1992
Etoposide in gastric cancerJ S Macdonald, K A Havlin
Cancer Treatment and Research|January 1, 1988
Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancerK A Havlin, D L Trump
The Journal of Infusional Chemotherapy|October 1, 1996
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancerL Chu, L M Sutton, B L Peterson, et al.
Journal of Interferon Research|August 1, 1989
Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gammaD M Paulnock, K A Havlin, B M Storer, et al.
Journal of Interferon Research|April 1, 1988
Lack of interferon production by dipyridamoleK A Havlin, A D Inglot, J K Willson, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
New anticancer agentsT D Brown, H A Burris, K A Havlin, et al.
Cancer|February 1, 1989
High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot studyK A Havlin, J G Kuhn, J W Myers, et al.
Cancer Research|December 1, 1991
A phase I clinical and pharmacokinetic trial of hepsulfamP M Ravdin, K A Havlin, M V Marshall, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancerK A Havlin, M J Ramirez, C M Legler, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
New anticancer agentsT D Brown, K A Havlin, J M Koeller, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|December 1, 1992
Etoposide in gastric cancerJ S Macdonald, K A Havlin
Cancer Treatment and Research|January 1, 1988
Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancerK A Havlin, D L Trump
The Journal of Infusional Chemotherapy|October 1, 1996
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancerL Chu, L M Sutton, B L Peterson, et al.
Journal of Interferon Research|August 1, 1989
Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gammaD M Paulnock, K A Havlin, B M Storer, et al.
Journal of Interferon Research|April 1, 1988
Lack of interferon production by dipyridamoleK A Havlin, A D Inglot, J K Willson, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
New anticancer agentsT D Brown, H A Burris, K A Havlin, et al.
Cancer|February 1, 1989
High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot studyK A Havlin, J G Kuhn, J W Myers, et al.
Cancer Research|December 1, 1991
A phase I clinical and pharmacokinetic trial of hepsulfamP M Ravdin, K A Havlin, M V Marshall, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancerK A Havlin, M J Ramirez, C M Legler, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
New anticancer agentsT D Brown, K A Havlin, J M Koeller, et al.
Pageof 2